Type 3 Autoimmune Pancreatitis: What Do We Know So Far?

Authors

Miłosz Caban, Barbara Włodarczyk, Łukasz Durko, Renata Talar-Wojnarowska

Published in

Digestive diseases and sciences. Jul 17, 2026. Epub Jul 17, 2026.

Abstract

The increasing use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to a rise in immune-related adverse events (irAEs). Type 3 autoimmune pancreatitis (AIP-3) has been proposed as a rare form of pancreatic injury induced by ICIs with autoimmune pancreatitis-like features and variable presentations. Its diagnosis is not straightforward. Moreover, the role of available therapeutic options, particularly mainly glucocorticosteroids (GCS), remains uncertain. Currently, there are no clear guidelines for AIP-3 management. Data on AIP-3 are derived mainly from small retrospective studies and provide limited-quality evidence. In addition, the diagnostic criteria and management of AIP-3 vary substantially between studies. Some researchers have classified asymptomatic pancreatic enzyme elevations during ICI therapy as AIP-3; however, isolated hyperlipasemia should not be considered sufficient for this diagnosis. This comprehensive, narrative review summarizes current knowledge about AIP-3 and discusses epidemiology, etiopathogenesis, clinical presentations, diagnosis, and treatment based on the most recent evidence.

PMID:
42467391
Bibliographic data and abstract were imported from PubMed on 17 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.